Peptide legal status, WADA status and human trial evidence
Most research peptides are not approved for human use anywhere, are prohibited in sport at all times under WADA Section S0 or S2, and have no published controlled human trials. Approved exceptions include semaglutide, tirzepatide and tesamorelin. The table below gives each compound's regulatory status, sport status and evidence base, with the source for each.
Regulatory and anti-doping status change. Verify any row against the current FDA record and the current WADA Prohibited List before acting on it, and discuss anything you intend to take with a licensed clinician.
How to read this table
Three separate questions get collapsed into the word 'legal' online, and they have different answers. Regulatory status is whether a medicines regulator has approved the compound for human use. Sport status is whether an anti-doping authority prohibits it. Evidence status is whether controlled human trials have been published. A peptide can be unapproved, banned in sport, and still widely sold — those facts do not contradict each other.
The table below separates the three so you can see which one applies to your situation. Nothing here is legal advice, and nothing here is a recommendation to use any compound.
- Approved: a regulator has reviewed safety and efficacy data and authorized human use.
- Not approved: no regulator has authorized it; sale is usually restricted to research labeling.
- Category 2 (FDA bulk substances): the FDA identified significant safety risks, which bars the substance from routine 503A pharmacy compounding.
- S0 (WADA): prohibited at all times because no regulatory authority has approved it for human therapeutic use.
- S2 (WADA): prohibited at all times as a peptide hormone, growth factor or related mimetic.
Peptide status reference table
| Peptide | US regulatory status | WADA status | Published human trials |
|---|---|---|---|
| BPC-157 | Not approved. FDA bulk substances Category 2 (significant safety risk) — not eligible for 503A compounding | Prohibited at all times, S0 (non-approved substance) | No controlled human efficacy trials published |
| TB-500 / thymosin beta-4 | Not approved for human use | Prohibited at all times, S2 (growth factors) | Early-phase trials of thymosin beta-4 exist; none for the TB-500 fragment sold online |
| Ipamorelin | Not approved. FDA bulk substances Category 2 | Prohibited at all times, S2 (GH secretagogues) | Small pharmacology studies only |
| CJC-1295 (with or without DAC) | Not approved. FDA bulk substances Category 2 | Prohibited at all times, S2 (GH secretagogues) | Phase 1 dose-escalation studies published |
| GHRP-2 / GHRP-6 | Not approved for human use | Prohibited at all times, S2 (GH secretagogues) | Small pharmacology studies only |
| Sermorelin | Previously FDA approved; brand withdrawn from the US market in 2008 | Prohibited at all times, S2 (GH secretagogues) | Yes — trials predate withdrawal |
| Semax / Selank | Not approved in the US, EU, UK or Australia; registered in Russia | Prohibited at all times, S0 | Russian-language trials; little peer-reviewed Western evidence |
| Melanotan II | Not approved. Subject of FDA and national regulator warnings | Not specifically listed; S0 applies as a non-approved substance | No approved-standard trials; adverse-event case reports published |
| Semaglutide | FDA approved (Ozempic, Wegovy, Rybelsus) | Not prohibited | Yes — large phase 3 program |
| Tirzepatide | FDA approved (Mounjaro, Zepbound) | Not prohibited | Yes — large phase 3 program |
| Retatrutide | Investigational; not approved anywhere | Not specifically listed; S0 applies as a non-approved substance | Yes — phase 2 published, phase 3 ongoing |
| Tesamorelin | FDA approved (Egrifta) for HIV-associated lipodystrophy | Prohibited at all times, S2 (GH secretagogues) | Yes — phase 3 program |
Why the FDA's 2023 bulk substances decision matters
Before 2023, several peptides reached people through compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. The FDA's review placed BPC-157, ipamorelin, CJC-1295 and others into Category 2, the bucket for substances with significant safety risks, which in practice removed the compounding route.
The effect was not that these peptides disappeared. It is that the remaining supply moved further toward unregulated sellers, where identity, sterility and potency are nobody's legal responsibility. If a clinic still offers one of these, it is worth asking exactly which pharmacy is producing it and under what authority.
What the WADA list does and does not cover
The Prohibited List is reissued every January and takes effect on 1 January. Section S0 is a catch-all: any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use is prohibited at all times. That single clause covers most research peptides even when they are never named individually.
Section S2 names peptide hormones, growth factors and related substances, including growth hormone secretagogues and their releasing peptides. Being unnamed on the list is therefore not evidence that a peptide is permitted — S0 usually catches it.
- 'Prohibited at all times' means in and out of competition.
- A Therapeutic Use Exemption applies only to approved medicines with a documented medical need.
- Supplement contamination is not a defense; athletes are strictly liable for what is in their sample.
Where 'human trial evidence' comes from in this table
The evidence column reports whether controlled trials in people have been published in indexed peer-reviewed literature, not whether people have used the compound. Rodent studies, cell-culture work and clinic case series are informative but they are not the same category of evidence, and dosing derived from them carries far wider uncertainty.
Where the column says no human trials exist, the honest conclusion is that nobody knows the safe dose, the safe duration, or the long-term risk profile in humans — including the people writing protocols online.
Keeping your own record straight
If you are working with a clinician on any of these, the useful thing to bring is a record: exactly which compound, which vial, which dose, on which dates, and what changed. That record is also what an anti-doping review or a medical workup will ask for, and it is the part people almost never have.
Frequently asked questions
- Are peptides legal to buy?
- In the United States most research peptides are legal to sell and buy only when labeled for laboratory research, not for human use. Selling them for injection, or marketing human dosing instructions, is what the FDA treats as unlawful. Possession rules differ by country, and several peptides are controlled substances in Australia and parts of Europe. Check your own jurisdiction before ordering anything.
- Is BPC-157 FDA approved?
- No. BPC-157 is not approved for human use in any indication. In 2023 the FDA placed it in Category 2 of its bulk drug substances review, meaning it identified significant safety risks for use in compounded preparations, which effectively removed it from legal compounding by US pharmacies.
- Which peptides does WADA ban?
- Growth hormone secretagogues such as ipamorelin, CJC-1295, GHRP-2 and GHRP-6 are prohibited at all times under Section S2 of the WADA Prohibited List. Peptides with no regulatory approval anywhere — a group that covers most research peptides — are prohibited at all times under Section S0. The list is reissued each January, so always check the current edition before competing.
- What does 'no human trials' actually mean?
- It means no controlled study in people has been published in the peer-reviewed literature for that compound and route. Dosing figures that circulate for those peptides come from rodent studies, in-vitro work, or user reports. Animal doses do not convert to human doses by bodyweight alone, so a confident-looking protocol can rest on no human evidence at all.
- Is a peptide legal if my clinic prescribes it?
- A licensed prescriber can legally prescribe an approved drug, including off-label. For unapproved peptides the situation is different: after the FDA's bulk substances decisions, several popular peptides can no longer be lawfully compounded in the US, so a clinic supplying them is operating outside that framework. Ask which specific product and pharmacy are being used.
- Does 'research chemical' labeling make it safe?
- No. That label is a legal position, not a quality claim. Research-grade vials are not held to pharmaceutical sterility, identity or potency standards, and independent testing repeatedly finds contents that differ from the label.
References & evidence
Sources cited on this page. Last reviewed September 2026. Corrections: editorial policy.
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under Section 503A — Category 2 list. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- World Anti-Doping Agency. The Prohibited List (current edition), Sections S0 and S2. https://www.wada-ama.org/en/prohibited-list
- U.S. Food and Drug Administration. Certain peptide drug products — compounding risk alert. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- U.S. National Library of Medicine, DailyMed. Approved prescribing information for semaglutide, tirzepatide and tesamorelin. https://dailymed.nlm.nih.gov/dailymed/
- ClinicalTrials.gov. Registered human studies for peptide compounds. https://clinicaltrials.gov/
- Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27–31. https://pubmed.ncbi.nlm.nih.gov/27057123/
Cite this page
Journalists, coaches and clinicians are welcome to reproduce this table with attribution to DoseRoutine and a link to https://doseroutine.com/peptides/legal-status. It is reviewed against the FDA bulk substances record and the current WADA Prohibited List.
Start free in DoseRoutineEducational reference only, not medical advice. Talk to a qualified clinician before starting, stopping or combining any peptide, supplement or medication.